Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Fulcrum Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
FULC
Nasdaq
8731
https://www.fulcrumtx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Fulcrum Therapeutics Inc
The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
- May 17th, 2024 12:04 pm
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
- May 16th, 2024 4:46 pm
Wall Street Analysts See a 69.15% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High?
- May 15th, 2024 1:55 pm
Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?
- May 14th, 2024 10:54 am
Fulcrum Therapeutics Inc (FULC) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
- May 14th, 2024 7:01 am
Sanofi strikes $1bn deal with Fulcrum for muscular dystrophy drug
- May 13th, 2024 3:02 pm
Fulcrum Therapeutics Q1 2024 Earnings: Misses Analyst Net Income Projections Amid Strategic ...
- May 13th, 2024 12:32 pm
Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug
- May 13th, 2024 11:47 am
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
- May 13th, 2024 11:00 am
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
- May 13th, 2024 10:00 am
Fulcrum Therapeutics to Participate in Upcoming May Conferences
- May 9th, 2024 12:00 pm
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
- May 8th, 2024 12:00 pm
Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
- May 6th, 2024 12:00 pm
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
- Mar 28th, 2024 8:05 pm
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mar 22nd, 2024 8:30 pm
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
- Mar 18th, 2024 11:00 am
CEO, President & Director of Fulcrum Therapeutics Alexander Sapir Buys More Stock
- Mar 7th, 2024 11:35 am
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
- Mar 5th, 2024 1:00 pm
Fulcrum Therapeutics Full Year 2023 Earnings: Beats Expectations
- Feb 28th, 2024 7:27 pm
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2023 Earnings Call Transcript
- Feb 28th, 2024 2:35 pm
Scroll